GOED shares insights on EPA/DHA finished product market and omega-3’s connection to ADHD

Published: 9-May-2024

The reports detail the trends the EPA and DHA markets are experiencing, as well as omega-3's impact on people with ADHD

The Global Organisation for EPA and DHA Omega-3s (GOED) recently published two reports on the EPA and DHA omega-3 industry: a biennial report on the global finished products market for EPA and DHA omega-3s and a scientific report on Attention Deficit Hyperactivity Disorder (ADHD) and omega-3s.


EPA and DHA finished products: a market insight

The 2024 Finished Product Report offers a comprehensive overview of six key markets: dietary supplements, pharmaceuticals, food and beverage, pet nutrition, infant formula and clinical nutrition/medical foods. 

Together, these categories reached USD $52.4bn in sales in 2023, primarily influenced by inflation and higher prices.

Some key takeaways from the report:

  • The pet nutrition segment exhibited strong growth of 8.8% annually, reaching $1.5 billion in sales in 2023
  • The supplement category also grew, but the dollar increase was driven primarily by increased prices as a result of fish oil shortages
  • The DHA-fortified infant nutrition market is by far the largest of the consumer product categories, although birth rates across the globe are on the decline, resulting in a growth of 2.9% in 2023
  • Looking ahead, sales of EPA and DHA finished products are poised to increase an average of 3.3% annually through 2025.

The report encompasses market statistics and trend analyses across 11 regions for 2022 and 2023, with forecasts extending through 2025.


Omega-3 and ADHD

The second report, EPA and DHA Supplementation and Attention Deficit Hyperactivity Disorder, explores the latest research on the impact of EPA+DHA omega-3 supplementation on ADHD and associated ADHD outcomes. 

The report was created using GOED’s Clinical Study Database (CSD), a powerful tool that catalogs all human clinical studies on EPA and DHA omega-3s.

EPA+DHA have been suggested to play a potential role in reducing the symptoms associated with ADHD and the report analyses the studies conducted on people who have been diagnosed with ADHD, or people who have been assessed using ADHD criteria for symptoms. 

The report also provides key takeaways and suggests next steps for research.

You may also like